Psilocybin is becoming the new cannabis as magic mushrooms find themselves in therapeutic use. What began as a ritual embibement thousands of years ago, could help doctors treat the human mind non-intrusively with an unheard of efficacy. The chemistry behind these little buttons of laughter could disrupt the treatment of conditions such as depression and anxiety as well as substance abuse.
Advocates and first moving market players are anxiously awaiting the inevitable rescheduling and legalization of psilocybin for research and medical use. Tripping balls for the thrill of it remains on the agenda so recreational psychedelics may also be in the cards while regulators come to grips with changing world opinion and an already burgeoning industry. Some medical professionals believe regulating psychedelics like alcohol and cannabis would be akin to regulating a nuclear weapon like you would a hand gun.
However, not much is understood about these mycogenous miracles but the research is beginning to mount and it points to a potentially positive future for magic mushrooms. Tune in!
3 Comments
Add Yours →So, what ticker companies are the Shrooms to invest in?
Hey Dave,
The field is pretty thin right now. But companies on the cusp are BOSS, WUHN, LITT. There’s also a few companies on the verge of going public which I wrote about here. https://equity.guru/2019/09/18/cambridge-houses-xfuture-event-spearheads-brave-new-world-psychedelic-treatments/
Check back in a couple hours for the latest BOSS news!
Ethan
Dave: We are about to launch a Pre-RTO round for a game changing technology.
Our team has identified a patentable method of producing psilocybin on a commercial scale that will change the economics of the industry.
Our chief scientist is a world leading biochemist and molecular biologist with extensive knowledge in operations, scale-up of fermentative API-production. He has used his expertise in DNA modeling to design and produce a unique DNA sequence that allows for time efficient and cost-effective psilocybin production.
If you want to learn more, email me @ marshall[at]ascentafinance.com